Start today for $99/mo · No results? No charge

Harbor
Get Started
Bupropion-NaltrexoneJanuary 16, 2026

Bupropion-Naltrexone for Binge Eating Disorder: An Emerging Treatment Option

Bupropion-Naltrexone for Binge Eating Disorder: An Emerging Treatment Option

Binge eating disorder (BED) is the most common eating disorder in the United States, yet it remains one of the most undertreated. Affecting an estimated 2.8% of adults over their lifetime, with prevalence roughly twice as high in women as in men, BED carries a clinical burden that extends well beyond the binge episodes themselves. Mood disorders, anxiety, substance use, and obesity cluster around BED with striking frequency, and the resulting impairment is substantial. More than 60% of people with BED report functional impairment, and nearly one in five experience it at a severe level.

For over a decade, clinicians have had exactly one FDA-approved pharmacotherapy to reach for: lisdexamfetamine (Vyvanse), a stimulant originally developed for ADHD. It works for many patients, but it carries its own limitations. Cognitive behavioral therapy remains the gold-standard psychological intervention, yet access is uneven, and waitlists are long. The result is a treatment gap that leaves the majority of BED patients without adequate care. By some estimates, fewer than half of people with BED ever seek treatment specifically for their eating disorder. This post discusses the use of naltrexone/bupropion in conjunction with behavioral therapies and other treatment modalities for binge eating disorder.

Why the Brain's Reward Circuitry Matters in Binge Eating

To understand why bupropion-naltrexone is a biologically plausible treatment for BED, you need to understand what's happening in the brain during a binge. BED is not simply a failure of willpower or a caloric surplus problem. Neuroimaging research has identified corticostriatal circuitry alterations in BED that closely mirror those observed in substance use disorders. Two neurotransmitter systems sit at the center of this:

  • Dopamine mediates the motivational "wanting" component of eating, the drive to seek out and obtain food.
  • Endogenous opioids, acting primarily through mu-opioid receptors, govern the hedonic "liking" component, the pleasure derived from consuming palatable food.

In BED, both systems appear dysregulated. Highly palatable foods produce exaggerated dopamine surges that strengthen the stimulus-reward association, while opioid hotspots in the nucleus accumbens shell and ventral pallidum amplify the hedonic response beyond what normal satiety signals can override.

eating disorder shown as a young girl rests her head on a dining table full of food while holding a fork

Mu-opioid receptors within the medial prefrontal cortex play a critical role in overeating, particularly by responding to food-associated environmental cues that trigger consumption despite satiation. This is the neurobiological signature of a binge. Eating that continues not because the body needs fuel, but because the reward circuitry has hijacked the decision-making process.

How Bupropion-Naltrexone Targets the POMC Pathway

The pharmacological rationale for combining bupropion and naltrexone rests on their complementary effects on the hypothalamic proopiomelanocortin (POMC) neuronal system and mesolimbic reward pathways:

  • Bupropion, a norepinephrine-dopamine reuptake inhibitor, stimulates POMC neurons through activation of dopamine D2 receptors. This increases firing of POMC neurons, boosts release of alpha-melanocyte-stimulating hormone (α-MSH), and signals downstream through melanocortin-4 receptors (MC4R) to reduce appetite and increase energy expenditure. But bupropion alone produces only modest effects on eating behavior. The reason is an autoinhibitory feedback loop: POMC neurons also produce beta-endorphin, which binds to mu-opioid receptors on those same neurons, dampening their activation. Bupropion turns the system on, but the brain's own opioids turn it back down.
  • Naltrexone, an opioid receptor antagonist, blocks that feedback loop. By inhibiting mu-opioid receptor binding, naltrexone prevents beta-endorphin from suppressing POMC neuron activity, allowing bupropion's stimulatory effect to persist. The result is a sustained increase in appetite-suppressing and satiety-promoting signaling that neither drug achieves on its own.

Beyond the hypothalamus, naltrexone also blocks opioid receptors in the ventral tegmental area and nucleus accumbens, reducing the opioid-mediated reward signal that highly palatable food generates. Animal studies have demonstrated that injecting either drug alone into the VTA reduces food consumption in fasted mice, but injecting both together produces a greater reduction than either alone. In human neuroimaging studies, the combination has been shown to reduce hypothalamic reactivity to food cues while simultaneously enhancing activation in brain regions associated with self-control, making food stimuli less compelling while strengthening the neural infrastructure for resisting them.

For BED specifically, this dual mechanism is compelling. The combination doesn't just reduce appetite. It addresses both the compulsive drive to binge (dopamine-mediated wanting) and the exaggerated pleasure response that reinforces the behavior (opioid-mediated liking). For resources on how this pathway works in practice, here's a guide to the POMC pathway, which provides an accessible breakdown of the underlying neuroscience.

What the Landmark Clinical Trials Show

The types of clinical studies, systematic reviews, and meta-analyses conducted to evaluate the use of naltrexone/bupropion for binge eating disorder, including details on study populations and outcome measures.

The Yale Randomized Controlled Trial

The most methodologically rigorous study to date was led by Carlos Grilo. This randomized, double-blind, placebo-controlled trial enrolled 136 adults with BED and co-occurring obesity (81.6% women; mean age 46.5 years) and assigned them to one of four 16-week treatment arms: placebo alone, naltrexone-bupropion alone, behavioral weight loss therapy (BWL) plus placebo, or BWL plus naltrexone-bupropion.

Binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37.1% in the BWL-plus-placebo group, and 57.1% in the combined BWL-plus-naltrexone-bupropion group. Naltrexone-bupropion was significantly superior to placebo, and BWL was significantly superior to no BWL. The combination of medication and behavioral therapy produced remission rates more than three times higher than placebo alone.

This study established two important things. First, naltrexone-bupropion has a measurable, independent effect on binge-eating behavior. It isn't just a weight-loss drug being repurposed without evidence. Second, combining it with structured behavioral therapy produces additive benefits that neither intervention achieves alone.

The Maintenance Treatment Trial

A critical follow-up question in BED pharmacotherapy is what happens when the medication stops. Relapse rates after treatment discontinuation have historically been high. Grilo and Gueorguieva addressed this directly in a 2023 trial.

Sixty-six patients (84.8% women, mean BMI 34.9 kg/m²) who had responded to acute treatments in the earlier trial were re-randomized to either naltrexone-bupropion or placebo for an additional 16 weeks. The intention-to-treat binge-eating remission rate was 68.8% for those who continued naltrexone-bupropion and 50.0% for those switched to placebo. More telling was the pattern within subgroups: patients who had responded to acute naltrexone-bupropion and were then switched to placebo showed significantly decreased probability of maintaining remission, increased binge-eating frequency, and no additional weight loss. Those who continued the medication maintained remission, kept binge frequency low, and achieved additional weight loss.

For patients who respond to naltrexone-bupropion acutely, maintenance treatment preserves the gains. This has practical implications for treatment planning. BED may require a longer pharmacotherapy window than a typical short-term trial design can capture.

Safety, Side Effects, and Tolerability

The safety profile and tolerability of naltrexone/bupropion in the treatment of binge eating disorder (BED) have been evaluated in several clinical trials and systematic reviews, generally indicating a favorable but nuanced risk-benefit balance. Most studies report that the combination is well-tolerated, with adverse effects that are typically mild to moderate in intensity and rarely necessitate discontinuation. The most commonly reported side effects include nausea, headache, constipation, dry mouth, dizziness, and insomnia, with nausea being the most frequent, especially during the initial titration period. These symptoms often diminish over time or can be managed by adjusting the dosing schedule. Importantly, serious adverse events such as hypertensive crises, seizures, or psychiatric complications are rare, but caution is warranted in individuals with a history of seizure disorders, eating disorders with purging behaviors, or uncontrolled hypertension, as bupropion is contraindicated in these populations. Additionally, naltrexone should not be used in patients requiring opioid analgesics due to the risk of precipitating withdrawal. Clinical trials have not demonstrated significant differences in discontinuation rates between naltrexone/bupropion and placebo groups, suggesting good overall tolerability. However, some evidence points to slightly higher dropout rates among individuals with heightened anxiety traits, underlining the importance of patient selection and monitoring. For carefully screened patients with BED, the naltrexone/bupropion combination offers a safe and manageable side effect profile, making it a promising adjunct or alternative to existing therapies.

unhealthy eating habits illustrated by a young woman sitting on the floor beside a scale and measuring tape

What the Meta-Analyses Reveal and Where Uncertainty Remains

A meta-analysis by Roudbaraki pooled four randomized controlled trials involving 444 participants. The analysis found that naltrexone-bupropion produced significant weight loss (mean difference of −3.57 kg, p<0.001) and significant BMI reduction (−1.24 kg/m², p<0.001) compared to controls, with no heterogeneity across studies. However, the pooled effect on binge-eating frequency did not reach statistical significance (mean difference −1.49 episodes, 95% CI −3.63 to 0.64, p=0.17).

The non-significant pooled result for binge frequency does not necessarily mean the drug doesn't work for binge eating. The meta-analyses included only three to four studies, a small base for detecting moderate effect sizes. The individual trials varied in design, outcome measures, and whether they paired medication with behavioral therapy. The Yale trial, which did pair the two, showed clear superiority for the combination. When behavioral therapy was absent, the medication's effect on binge frequency was less consistent. The emerging picture is that naltrexone-bupropion's role in BED treatment may be most pronounced when used as part of a multimodal approach, medication plus structured behavioral intervention, rather than as a standalone pharmacotherapy.

Where Bupropion-Naltrexone Fits in the BED Treatment Landscape

Positioning naltrexone-bupropion within the current BED treatment framework requires acknowledging what it is and what it isn't. There are current clinical guidelines and recommendations regarding the use of naltrexone/bupropion for the treatment of binge eating disorder. It is not a first-line treatment. Cognitive behavioral therapy retains that role, and lisdexamfetamine remains the only FDA-approved pharmacotherapy for BED.

What it appears to be is a pharmacologically rational option for a specific clinical profile: BED patients with co-occurring obesity who have not responded adequately to first-line interventions, particularly when food addiction features, reward-driven eating, or significant weight management needs are present. The dual mechanism addressing both dopamine-mediated craving and opioid-mediated hedonic eating provides a theoretical and empirical basis that few other available medications match.

The maintenance treatment data from Grilo's 2023 study adds another dimension. For patients who do respond, the evidence suggests that sustained treatment is important, a finding that aligns with how clinicians already think about medications for conditions like depression, where acute response without maintenance therapy often leads to relapse. In the broader context of weight management, where platforms like Harbor emphasize physician-guided programs with structured treatment timelines and built-in support, the idea that BED pharmacotherapy may require deliberate planning around treatment duration, rather than indefinite or arbitrarily short courses, resonates with emerging best practices.

It's also worth noting that naltrexone-bupropion's weight-reduction effects (an average of roughly 3.5 kg over 12–16 weeks) are clinically meaningful for BED patients with obesity, even when binge-frequency reduction doesn't reach statistical significance in pooled analyses. Weight gain exacerbates the medical comorbidities of BED, and medications that address both the behavioral and metabolic dimensions of the disorder have value that pure binge-frequency metrics may understate.

What Comes Next: The Research Still Needed

The current evidence base is promising but thin. Four randomized controlled trials with a combined enrollment of fewer than 500 participants are not enough to establish definitive treatment guidelines. Several gaps need to be addressed.

  • Larger, longer trials are the most pressing need. The existing studies have followed patients for 12 to 16 weeks; BED is a chronic, relapsing condition that requires evidence on outcomes over six months, one year, and beyond. The maintenance study from Grilo is a start, but replication with larger samples is essential.
  • Head-to-head comparisons with lisdexamfetamine would clarify where each medication fits. No trial has directly compared the two, and the patient populations most likely to benefit from each may differ. Lisdexamfetamine's mechanism partially overlaps with bupropion's, but the addition of naltrexone's opioid blockade represents a distinct pharmacological strategy.
  • Subgroup analyses are needed to identify which BED patients respond best. The Italian open-label trial's observation that patients with food addiction features showed particular improvement deserves rigorous follow-up. If naltrexone-bupropion is most effective for the subgroup of BED patients with prominent reward dysregulation and addiction-like eating patterns, that would sharpen its clinical positioning considerably.
  • Combination protocols with behavioral therapy need standardization. The Yale trial's finding that naltrexone-bupropion plus behavioral weight-loss therapy produced a 57.1% remission rate suggests the combination is where the strongest effects lie, but which behavioral interventions pair best with the medication, and how they should be sequenced, remain undefined.

Real-world effectiveness data from clinical practice settings, beyond the controlled conditions of randomized trials, will be critical. BED patients in clinical practice are more heterogeneous than trial populations, and understanding how the medication performs outside research settings will determine its practical utility.

problematic relationship with food depicted as a woman lying on a couch pushing away plates of cookies and salad

Frequently Asked Questions

Below are concise answers to common questions about the biological and pharmacological mechanisms by which naltrexone and bupropion may impact binge eating behaviors, including the role of the opioid system and neurotransmitter modulation.

How does the opioid system influence binge eating behaviors?

The opioid system, especially mu-opioid receptors, amplifies the pleasure (“liking”) from palatable foods, reinforcing binge eating by making high-calorie foods more rewarding and harder to resist.

What role does dopamine play in BED?

Dopamine drives the motivational “wanting” aspect of eating, increasing the urge to seek out and consume food, particularly in response to environmental cues and stress.

How does bupropion affect the brain’s reward and appetite pathways?

Bupropion increases dopamine and norepinephrine levels, stimulating proopiomelanocortin (POMC) neurons in the hypothalamus, which leads to appetite suppression and increased energy expenditure.

Why is naltrexone added to bupropion for BED?

Naltrexone blocks mu-opioid receptors, preventing the brain’s natural opioids from dampening POMC neuron activity, thereby sustaining bupropion’s appetite-suppressing effects and reducing food-related pleasure.

How does the combination of bupropion-naltrexone differ from each drug alone?

Together, bupropion and naltrexone provide a dual approach: bupropion increases satiety signals, while naltrexone blocks the hedonic feedback, resulting in a more sustained reduction in both food cravings and reward-driven eating.

What is the significance of the POMC pathway in BED treatment?

The POMC pathway regulates appetite and satiety. By activating this pathway and preventing its inhibition, the bupropion-naltrexone combination helps curb binge eating episodes more effectively than targeting a single neurotransmitter system.

Can this combination impact both the urge and the pleasure of binge eating?

Yes, the combination addresses the motivational “wanting” (dopamine) and the hedonic “liking” (opioid) components, reducing both the drive to binge and the pleasure derived from binge episodes.

Does naltrexone-bupropion affect other brain regions beyond the hypothalamus?

Yes, it also targets the ventral tegmental area and nucleus accumbens, reducing the reward response to food cues and strengthening self-control circuits.

Binge eating disorder has suffered from a scarcity of pharmacotherapy options for too long. For a condition affecting millions of people, every credible addition to the therapeutic toolkit matters. Bupropion-naltrexone is not yet that addition in the formal sense. But the direction of the evidence is encouraging. The Yale trial demonstrated meaningful remission rates that improved further with behavioral therapy. For patients with BED who have not found relief with existing options, bupropion-naltrexone represents something increasingly rare in the eating disorder treatment landscape: a pharmacotherapy with a clear biological rationale, a growing evidence base, and a realistic path toward establishing its place in clinical practice. The next few years of research will determine how far that path extends.

Sources: